INS and anemia (phenotype): Despite the positive effects of rosiglizatone, such as lowering fasting plasma glucose (FPG) and postprandial serum glucose, lowering HbA1c, and lowering insulin and C-peptide levels, this drug has clinically significant side effects such as edema, anemia, and weight gain [252].